Teleflex Inc. stock (US8793691069): Q1 2026 beat and upcoming earnings keep focus on NYSE-listed medtech group

Teleflex Inc. shares on the NYSE remain in focus after the United States-based medical technology company delivered a Q1 2026 earnings beat and investors look ahead to the next estimated earnings date in late July 2026.

Teleflex Inc. shares on the New York Stock Exchange remain in focus for U.S. investors after the Wayne, Pennsylvania-based medical technology group delivered an earnings beat for Q1 2026 and the market now looks ahead to the next estimated quarterly report in late July 2026, according to MarketBeat as of 05/07/2026.

For Q1 2026, Teleflex reported earnings per share of USD 1.39, ahead of the consensus estimate of USD 1.21, and quarterly revenue of USD 548.30 million, which exceeded analyst expectations of USD 536.91 million, based on data compiled by MarketBeat as of 05/07/2026.

The company is listed in the United States on the NYSE under the ticker TFX and is part of the domestic healthcare and medical technology universe that many U.S.-based institutional and retail investors follow through benchmarks such as the S&P 500 healthcare segment and sector-specific indices.

According to MarketBeat, Teleflex shares traded at USD 125.58, down 1.48% on the day, as of 02:06 PM Eastern on a recent trading session, underscoring how the stock continues to react to both company news and broader U.S. equity market conditions.

The stock traded at USD 125.58 on the NYSE on 05/07/2026, according to MarketBeat as of 05/07/2026.

Although Teleflex is primarily a U.S.-listed name, the shares are also accessible to European and German investors via local trading venues such as Tradegate and Frankfurt, where the stock is quoted in EUR, providing an additional point of access outside regular U.S. trading hours for international market participants.

Beyond the Q1 numbers, MarketBeat notes that Teleflex has provided earnings per share guidance for the current period in a range of USD 6.25 to USD 6.55, compared to a consensus of USD 6.73, and revenue guidance around USD 2.3 billion versus similar aggregated expectations, giving the U.S. market a framework for 2026 performance.

The company also remains active in corporate financing, with Business Wire reporting that Teleflex priced a private offering of USD 500 million of senior notes to refinance existing debt, which forms part of its broader capital structure and balance sheet management strategy.

As of: 03.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Teleflex Inc.
• Sector/industry: Medical technology and devices
• Headquarters/country: Wayne, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Vascular access, interventional cardiology and anesthesia-related single-use medical devices
• Home exchange/listing venue: New York Stock Exchange (TFX)
• Trading currency: USD

Teleflex Inc.: core business model

Teleflex focuses on designing and supplying specialty single-use medical devices for critical care, surgical, anesthesia and interventional procedures, with revenue mainly generated from hospitals and healthcare providers using its vascular access, anesthesia, and interventional product lines.

Teleflex Inc. in peer comparison

On a sector basis, Teleflex is often compared with other U.S.-listed medical technology companies that supply invasive and minimally invasive devices to hospitals and clinics. Typical reference points include mid- to large-cap medtech names on the NYSE and Nasdaq that derive a high proportion of revenue from single-use devices and critical care consumables.

While direct peers in this specialized segment can vary by product line, the market tends to evaluate Teleflex alongside other diversified device makers on metrics such as year-on-year revenue growth, margin development and earnings guidance, and the Q1 2026 revenue increase of 32.3% year-over-year to USD 548.30 million offers investors a concrete benchmark for how it is currently scaling compared with the broader U.S. medical device universe.

Conclusion

Teleflex Inc. remains a closely watched U.S. medical technology stock after its Q1 2026 earnings beat and double-digit year-on-year revenue growth, which highlighted the performance of its portfolio of single-use devices used in critical care and interventional procedures.

In peer comparison, the company is assessed against other NYSE and Nasdaq-listed medtech names on growth, profitability and guidance metrics, and the combination of its USD 6.25 to USD 6.55 EPS guidance range and the estimated late-July 2026 earnings date will be important markers for how it tracks against sector averages going forward.

With a recent USD 500 million senior notes offering used to refinance debt and an active U.S. listing on the NYSE, Teleflex continues to balance operational growth in its core business with capital structure management that will be monitored alongside future quarterly earnings disclosures.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.